PYRAMID-ANALYTICS
31.3.2022 16:37:11 CEST | Business Wire | Press release
Experts from Delaware and Pyramid Analytics will explore why and how Decision Intelligence – what’s next in analytics and business intelligence (ABI) – should be introduced into enterprise platforms at the UKISUG Analytics Symposium , an annual event for the independent UK & Ireland SAP User Group being held on 5 April, 2022 at The Vox Conference Centre, Birmingham. The conference offers the opportunity for networking and collaboration among peers specialising in SAP Analytics Cloud, data preparation, platform & database and digital transformation.
UKISUG Analytics Symposium is free to attend. Register here .
Key Points:
- Delaware’s Analytics Lead and Pyramid’s Director of Product Management will discuss Decision Intelligence and how to introduce it into an SAP business and technology ecosystem.
- Delaware implements the Pyramid Decision Intelligence Platform across the UK & Ireland to help organisations leverage the full value of data by providing AI-powered analytics to all decision-makers.
- Both companies have partnerships with SAP and expertise in the SAP technology ecosystem .
- Pyramid Analytics is an official member of the SAP® PartnerEdge® open ecosystem. Pyramid Platform is certified by SAP Certified for SAP BW/4HANA, SAP HANA, and SAP NetWeaver.
Attendees, Mark Your Diaries
Chris Houlder, Analytics Lead at Delaware, and Ian MacDonald, Director of Product Management with Pyramid, will discuss how enterprises running on SAP can best understand their data and how to react to fast-changing conditions, and address the challenges of adopting a holistic platform that works directly on both SAP BW and SAP HANA. The session will also include a demo of the Pyramid Analytics Decision Intelligence platform and how to get more value from these SAP investments. The session begins at 10 a.m. GMT.
Partnership Brings Decision Intelligence to Enterprises Across the UKI
Pyramid Analytics and global IT services company Delaware have a partnership agreement through which the companies jointly sell and implement the Pyramid Platform for decision intelligence and provide consulting services. The partnership puts the Pyramid Platform for decision intelligence into the hands of more than 3,000 Delaware consultants. The Pyramid Platform uniquely combines Data Preparation, Business Analytics, and Data Science in a single Analytics and Business Intelligence (ABI) environment. Leading technology analysts BARC, Dresner Advisory Services, and Gartner rank Pyramid first in critical ABI capabilities .
Pyramid and Delaware have strong partnerships with SAP, the world’s largest provider of Enterprise Application Software. Delaware and Pyramid Analytics jointly deliver solutions enabling customers to integrate sophisticated SAP data sets and non-SAP sources, from a wide range of on-premises and cloud-based data sources, without moving or ingesting the data, through a single decision intelligence platform.
Many of Delaware’s clients have complex landscapes and face challenges pulling together accurate and coherent reporting. Pyramid enables all users, from data scientists to non-technical business users, to maximise their investments in SAP providing for the fastest, direct querying and analytics on BW, BEx, HANA, CDS and IQ, while maintaining the investment in business logic and security designed into SAP — all within a complete point and click, no-code, governed self-service analytics environment.
Quotes
Ian Macdonald, Director of Product Management, Pyramid Analytics : “Business success in today’s dynamic markets requires organizations to react to trends and opportunities in real time with accuracy, speed and scale. Data drives better decisions. However, due to legacy tool limitations, integration issues and data management challenges, many SAP customers struggle to expose all the necessary data to deliver modern self-service analytic capabilities. Pyramid Decision Intelligence Platform allows business users to get more value out of their existing SAP BW and SAP HANA investments, delivering best-in-class functionality and performance that preserves the security and governance inherent in the SAP platform.”
Complete, Unified Decision Intelligence
Pyramid’s Decision Intelligence Platform unifies Data Preparation, Business Analytics, and Data Science on a single, integrated platform. This eliminates the need to use multiple disparate tools and the associated license cost and management complexity. Lower Total Cost of Ownership (TCO), rapid rollout, quicker and direct access to all available data, and industry-leading user adoption means faster time to value. Pyramid’s Decision Intelligence Platform can be deployed on-premises, into a private or public cloud, embedded into other apps or delivered through Managed Services Providers (MSP).
About Delaware
Delaware is a fast-growing, global company that delivers advanced solutions and services to organisations striving for a sustainable, competitive advantage. Delaware guides its customers through their business transformation, applying the ecosystems of its main business partners, SAP and Microsoft. Delaware continues to service its customers afterwards, assuring continuity and continuous improvement. Delaware has over 3000 professionals in 24 offices around the world. For more information, please visit www.delaware.co.uk .
About Pyramid Analytics
Pyramid is what’s next in analytics. Our unified decision intelligence platform delivers insights for everyone to make faster, more informed decisions. It provides direct access to any data, enables governed self-service for any person, and serves any analytics need in a no-code environment. The Pyramid Decision Intelligence Platform uniquely combines Data Prep, Business Analytics, and Data Science in a single environment with AI guidance, reducing cost and complexity while accelerating growth and innovation. The Pyramid Platform enables a strategic, organization-wide approach to Business Intelligence and Analytics, from the simple to the sophisticated. Schedule a demo .
Pyramid Analytics is incorporated in Amsterdam and has regional headquarters in global innovation and business centers, including London, New York City, and Tel-Aviv. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Investors include Jerusalem Venture Partners (JVP), Sequoia Capital and Viola Growth. Learn more at Pyramid Analytics .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220331005705/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom